Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

This phase II trial studies the side effects of erlotinib hydrochloride (350 mg po once
weekly for up to 6 months) and how well it works in reducing duodenal polyp burden in
patients with familial adenomatous polyposis at risk of developing colon cancer. Erlotinib
hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.


Erlotinib, Erlotinib Hydrochloride


Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis


Niloy J Samadder

See list of participating sites